1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 10, 2024.
The trade is 100.0% of the 400,000 shares held after it.
No other insider bought within 30 days.
Insider activity: Marketing/Merger/Acq. Officer HADFIELD JAMIE bought about $200.0K of CRWE on Jul 12, 2024, the largest insider purchase at the company on our record.
1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 20, 2024.
The trade is 0.0% of the 10,015,057 shares held after it.
1 other insider bought within 30 days.
Insider activity: Insider Mike Zaman Irrevocable Trust bought about $1.3K of CRWE on Jun 10, 2024, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$633
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CRWE
FY Dec 2025
$777
FY Dec 2024
$1.4K
FY Dec 2023
$112
FY Dec 2022
$2.9K
FY Dec 2021
$15.7K
Jun 2026
$154
Mar 2026
$0
Dec 2025
$200
Sep 2025
$279
Jun 2025
$163
Mar 2025
$135
Dec 2024
$612
Sep 2024
$369
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
0.91x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1,668%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CRWE
FY Dec 2025
-1,826%
FY Dec 2024
n/a
FY Dec 2023
-12,883%
FY Dec 2022
-243.1%
FY Dec 2021
-112.4%
Jun 2026
-1,668%
Mar 2026
-3,800%
Dec 2025
-1,826%
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
-184,866%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.1M
market value at close 2026-10-26 on 2026-08-13 shares, plus LongTermDebt as filed 2023-12-31 (30 months older than the period end) (includes the current portion), minus cash 2022-06-30
Enterprise value CRWE
FY Dec 2025
$16.5M
FY Dec 2024
$12.7M
FY Dec 2023
$6.0M
FY Dec 2022
$16.9M
FY Dec 2021
$23.3M
Jun 2026
$6.8M
Mar 2026
$13.1M
Dec 2025
$16.5M
Sep 2025
$16.5M
Jun 2025
$47.7M
Mar 2025
$13.3M
Dec 2024
$12.7M
Sep 2024
$18.8M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing CRWE
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
6 not measured: Profitability, Financial health, Insider conviction, Institutional and government, Risk and compliance, US patents
Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; no debt to cover
Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.